首页 > 最新文献

Obesity Pillars最新文献

英文 中文
Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study GLP-1受体激动剂对成人2型糖尿病患者营养缺乏和肌肉损失的影响:一项回顾性观察研究
Pub Date : 2025-06-10 DOI: 10.1016/j.obpill.2025.100186
W. Scott Butsch , Suela Sulo , Andrew T. Chang , Jeeyun A. Kim , Kirk W. Kerr , Dominique R. Williams , Refaat Hegazi , Thadchaigeni Panchalingam , Scott Goates , Steven B. Heymsfield

Background

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) drug-induced weight loss is associated with fat mass reduction but can also lead to nutritional deficiencies and loss of muscle. We quantified nutritional deficiencies in adults who had undergone GLP-1RA treatment.

Methods

This was an observational, retrospective analysis of de-identified patient-level claims data from 461,382 adults newly prescribed GLP-1RAs between 7/2017 and 12/2021 with no prior diagnoses of nutritional deficiencies. While most patients had type 2 diabetes (T2DM), the population also included individuals with type 1 diabetes (T1DM), prediabetes, or no recorded diabetes diagnosis. A secondary propensity-matched analysis compared GLP-1RA users with non-users. The matched comparator cohort consisted of adults with type 2 diabetes treated with metformin but not prescribed GLP-1RAs, whereas GLP-1RA users were treated with both metformin and GLP-1RA. Nutritional deficiencies were assessed at 6 and 12 months after GLP-1RA initiation. Nutritional deficiency diagnoses or complications were compared between patients with or without a dietitian visit within a 6-months of treatment initiation.

Results

Patients were mainly female (56.3 %), mean age (±SD) 52.9 (±11.7) years, with obesity (44.9 %) or overweight (5.6 %); type 2 diabetes (80.5 %) and hypertension (66.3 %) were the most common comorbidities. Nutritional deficiencies were diagnosed in 12.7 % of the patients within 6 months after GLP-1RA initiation and in 22.4 % within 12 months. Vitamin D deficiency was most common, having an incidence of 7.5 % and 13.6 % within 6 and 12 months, respectively. Recorded nutrient deficiencies or deficiency-related complications were more likely among patients with a dietitian visit within the first 6 months of GLP-1RA initiation compared to patients without a dietitian visit.

Conclusion

Over 20 % had nutritional deficiencies diagnosed within one-year of starting GLP-1RA treatment. These findings highlight the importance of nutritional screening and diagnosis of deficiencies and inclusion of physician nutrition specialists, dietitians, and other nutrition care specialists in patient care.
胰高血糖素样肽-1受体激动剂(GLP-1RAs)药物诱导的体重减轻与脂肪减少有关,但也可能导致营养缺乏和肌肉损失。我们量化了接受GLP-1RA治疗的成年人的营养缺乏症。这是一项观察性、回顾性分析,对2017年7月至2021年12月期间新开GLP-1RAs的461,382名未确诊营养缺乏症的成年人的患者水平索赔数据进行了分析。虽然大多数患者患有2型糖尿病(T2DM),但人群中也包括患有1型糖尿病(T1DM)、糖尿病前期或无糖尿病诊断记录的个体。二级倾向匹配分析比较了GLP-1RA使用者和非使用者。匹配的比较组包括接受二甲双胍治疗但未开GLP-1RA处方的成人2型糖尿病患者,而GLP-1RA使用者同时接受二甲双胍和GLP-1RA治疗。在GLP-1RA启动后6个月和12个月评估营养缺乏症。在治疗开始的6个月内,比较有或没有营养师访问的患者的营养缺乏症诊断或并发症。结果患者以女性为主(56.3%),平均年龄(±SD) 52.9(±11.7)岁,肥胖(44.9%)或超重(5.6%);2型糖尿病(80.5%)和高血压(66.3%)是最常见的合并症。12.7%的患者在GLP-1RA开始治疗后6个月内诊断出营养缺乏,22.4%的患者在12个月内诊断出营养缺乏。维生素D缺乏症最为常见,在6个月和12个月内的发病率分别为7.5%和13.6%。与未接受GLP-1RA治疗的患者相比,在GLP-1RA开始治疗的前6个月内接受营养师访问的患者更容易出现营养缺乏或营养不足相关并发症。结论超过20%的患者在开始GLP-1RA治疗的一年内被诊断为营养缺乏。这些发现强调了营养筛查和缺陷诊断的重要性,以及医生营养专家、营养师和其他营养护理专家参与患者护理的重要性。
{"title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study","authors":"W. Scott Butsch ,&nbsp;Suela Sulo ,&nbsp;Andrew T. Chang ,&nbsp;Jeeyun A. Kim ,&nbsp;Kirk W. Kerr ,&nbsp;Dominique R. Williams ,&nbsp;Refaat Hegazi ,&nbsp;Thadchaigeni Panchalingam ,&nbsp;Scott Goates ,&nbsp;Steven B. Heymsfield","doi":"10.1016/j.obpill.2025.100186","DOIUrl":"10.1016/j.obpill.2025.100186","url":null,"abstract":"<div><h3>Background</h3><div>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) drug-induced weight loss is associated with fat mass reduction but can also lead to nutritional deficiencies and loss of muscle. We quantified nutritional deficiencies in adults who had undergone GLP-1RA treatment.</div></div><div><h3>Methods</h3><div>This was an observational, retrospective analysis of de-identified patient-level claims data from 461,382 adults newly prescribed GLP-1RAs between 7/2017 and 12/2021 with no prior diagnoses of nutritional deficiencies. While most patients had type 2 diabetes (T2DM), the population also included individuals with type 1 diabetes (T1DM), prediabetes, or no recorded diabetes diagnosis. A secondary propensity-matched analysis compared GLP-1RA users with non-users. The matched comparator cohort consisted of adults with type 2 diabetes treated with metformin but not prescribed GLP-1RAs, whereas GLP-1RA users were treated with both metformin and GLP-1RA. Nutritional deficiencies were assessed at 6 and 12 months after GLP-1RA initiation. Nutritional deficiency diagnoses or complications were compared between patients with or without a dietitian visit within a 6-months of treatment initiation.</div></div><div><h3>Results</h3><div>Patients were mainly female (56.3 %), mean age (±SD) 52.9 (±11.7) years, with obesity (44.9 %) or overweight (5.6 %); type 2 diabetes (80.5 %) and hypertension (66.3 %) were the most common comorbidities. Nutritional deficiencies were diagnosed in 12.7 % of the patients within 6 months after GLP-1RA initiation and in 22.4 % within 12 months. Vitamin D deficiency was most common, having an incidence of 7.5 % and 13.6 % within 6 and 12 months, respectively. Recorded nutrient deficiencies or deficiency-related complications were more likely among patients with a dietitian visit within the first 6 months of GLP-1RA initiation compared to patients without a dietitian visit.</div></div><div><h3>Conclusion</h3><div>Over 20 % had nutritional deficiencies diagnosed within one-year of starting GLP-1RA treatment. These findings highlight the importance of nutritional screening and diagnosis of deficiencies and inclusion of physician nutrition specialists, dietitians, and other nutrition care specialists in patient care.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100186"},"PeriodicalIF":0.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144272469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system 城市安全网医院系统中训练有素和在职初级保健提供者关于肥胖的知识、态度和做法
Pub Date : 2025-06-06 DOI: 10.1016/j.obpill.2025.100185
Alejandro Campos , Kathryn L. Fantasia , Ivania Rizo

Background

Obesity is a highly prevalent, chronic, and treatable disease that disproportionately impacts some minoritized populations who seek care in safety-net settings. Given that primary care providers (PCPs) often serve as the initial point of contact for patients, we aimed to assess their knowledge, attitudes, and practices related to management of obesity.

Methods

This was a cross-sectional study conducted to assess knowledge, attitudes, and practices on obesity management through an anonymous, electronic survey among trained (MD/DO and NP) and in-training (residents) primary care providers (PCPs) in the Departments of Internal Medicine and Family Medicine within an urban safety-net healthcare system.

Results

Among 350 sampled, 96 PCPs completed the survey (27 % response rate). Participants were predominantly (60.4 %) Internal Medicine trainees. The majority of PCPs accurately identified common weight-related comorbidities and improvement of these with >10 % weight loss. Only 25 % of PCPs correctly identified both body mass index (BMI) criteria for anti-obesity medication (AOM) prescription and only 9.1 % identified both BMI criteria for bariatric surgery. Nearly two-thirds (64 %) of PCPs reported prescribing AOMs, with greater comfort in using glucagon like peptide-1 receptor agonist (GLP-1 RA) injectable agents (semaglutide and liraglutide) than with older oral AOMs (phentermine, phentermine-topiramate, and naltrexone-bupropion). Knowledge about side effects and insurance coverage were reported as influencing AOM prescription. Time constraints and lack of training and/or knowledge were identified as barriers in obesity management by more than 50 % of PCPs.

Conclusions

Our study highlights gaps in obesity-related knowledge and practice among PCPs, emphasizing the need for enhanced training, clinical support, and policy reforms to improve obesity management and patient outcomes.
背景:肥胖是一种非常普遍的、慢性的、可治疗的疾病,对一些在安全网环境中寻求治疗的少数群体产生了不成比例的影响。鉴于初级保健提供者(pcp)经常作为患者的初始接触点,我们旨在评估他们的知识、态度和与肥胖管理相关的实践。方法本研究是一项横断面研究,旨在通过匿名电子调查,对城市安全网医疗保健系统内内科和家庭医学部培训过的(MD/DO和NP)和正在培训的(住院医师)初级保健提供者(pcp)进行评估肥胖管理的知识、态度和实践。结果在350份抽样调查中,96名执业医师完成问卷调查,回复率为27%。参与者主要是内科实习生(60.4%)。大多数pcp准确地确定了常见的体重相关合并症,并通过体重减轻10%来改善这些合并症。只有25%的pcp正确识别抗肥胖药物(AOM)处方的体重指数(BMI)标准,只有9.1%的pcp正确识别减肥手术的BMI标准。近三分之二(64%)的pcp报告使用AOMs,使用胰高血糖素样肽-1受体激动剂(GLP-1 RA)注射剂(semaglutide和liraglutide)比使用较老的口服AOMs(芬特明、芬特明-托吡酯和纳曲酮-安非他酮)更舒适。对副作用的了解和保险范围是影响AOM处方的因素。超过50%的pcp认为时间限制和缺乏培训和/或知识是肥胖管理的障碍。结论本研究突出了pcp在肥胖相关知识和实践方面的差距,强调需要加强培训、临床支持和政策改革,以改善肥胖管理和患者预后。
{"title":"Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system","authors":"Alejandro Campos ,&nbsp;Kathryn L. Fantasia ,&nbsp;Ivania Rizo","doi":"10.1016/j.obpill.2025.100185","DOIUrl":"10.1016/j.obpill.2025.100185","url":null,"abstract":"<div><h3>Background</h3><div>Obesity is a highly prevalent, chronic, and treatable disease that disproportionately impacts some minoritized populations who seek care in safety-net settings. Given that primary care providers (PCPs) often serve as the initial point of contact for patients, we aimed to assess their knowledge, attitudes, and practices related to management of obesity.</div></div><div><h3>Methods</h3><div>This was a cross-sectional study conducted to assess knowledge, attitudes, and practices on obesity management through an anonymous, electronic survey among trained (MD/DO and NP) and in-training (residents) primary care providers (PCPs) in the Departments of Internal Medicine and Family Medicine within an urban safety-net healthcare system.</div></div><div><h3>Results</h3><div>Among 350 sampled, 96 PCPs completed the survey (27 % response rate). Participants were predominantly (60.4 %) Internal Medicine trainees. The majority of PCPs accurately identified common weight-related comorbidities and improvement of these with &gt;10 % weight loss. Only 25 % of PCPs correctly identified both body mass index (BMI) criteria for anti-obesity medication (AOM) prescription and only 9.1 % identified both BMI criteria for bariatric surgery. Nearly two-thirds (64 %) of PCPs reported prescribing AOMs, with greater comfort in using glucagon like peptide-1 receptor agonist (GLP-1 RA) injectable agents (semaglutide and liraglutide) than with older oral AOMs (phentermine, phentermine-topiramate, and naltrexone-bupropion). Knowledge about side effects and insurance coverage were reported as influencing AOM prescription. Time constraints and lack of training and/or knowledge were identified as barriers in obesity management by more than 50 % of PCPs.</div></div><div><h3>Conclusions</h3><div>Our study highlights gaps in obesity-related knowledge and practice among PCPs, emphasizing the need for enhanced training, clinical support, and policy reforms to improve obesity management and patient outcomes.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100185"},"PeriodicalIF":0.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144253434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of lifestyle modification counselling on weight and body composition among adults with overweight or obesity on antiretroviral therapy: a randomized controlled trial 生活方式改变咨询对接受抗逆转录病毒治疗的超重或肥胖成人体重和身体成分的影响:一项随机对照试验
Pub Date : 2025-06-06 DOI: 10.1016/j.obpill.2025.100184
Agete Tadewos Hirigo , Moges Derbe , Daniel Yilma , Ayalew Astatkie , Zelalem Debebe

Background

we aimed to evaluate the impact of lifestyle modification counselling on weight and body composition among adults with overweight or obesity receiving antiretroviral treatment (ART).

Methods

This randomized, open-label, controlled trial enrolled 126 adults aged 18–65 years, living with human immunodeficiency virus (HIV) and classified as overweight or obese. Of these, 116 participants (63 in the control group and 53 in the intervention group) completed the six-month follow-up. Weight and body composition outcomes were analyzed among those who completed the study, with comparisons made between baseline and post-intervention measurements. The effect of lifestyle modification counselling on weight and body composition was evaluated through linear mixed effects model and multiple linear regression analysis.

Results

Over the six-month trial, participants who received lifestyle modification counselling showed significantly greater reductions in body weight (Δ = −1.4 kg, p = 0.002), visceral fat (Δ = −0.53, p = 0.006), fat mass (Δ = −2.16 kg, p ​< ​0.001), and body fat percentage (Δ ​= ​−2.02 ​%, p ​< ​0.001) compared to the control group. The intervention group experienced greater increases in fat-free mass (Δ ​= ​+0.673 kg, p ​= ​0.068) and percentage skeletal muscle (Δ ​= ​+1.27 ​%, p ​< ​0.001) compared to the control group. Additionally, lifestyle modification counselling significantly contributed to achieving at least a 3 ​% weight loss from baseline (β ​= ​0.158, p ​= ​0.048).

Conclusion

Lifestyle modification counselling resulted in promising and favorable changes in weight and body composition. Therefore, offering routine structured counselling interventions within ART clinics for individuals with overweight or obesity may help reduce obesity-related health risks and improve clinical outcomes (Thai Clinical Trials Registry TCTR20240905007).
背景:我们旨在评估生活方式改变咨询对接受抗逆转录病毒治疗(ART)的超重或肥胖成年人体重和身体组成的影响。方法:这项随机、开放标签、对照试验招募了126名年龄在18-65岁、携带人类免疫缺陷病毒(HIV)、超重或肥胖的成年人。其中,116名参与者(对照组63名,干预组53名)完成了为期6个月的随访。对完成研究的人的体重和身体组成结果进行了分析,并对基线和干预后的测量结果进行了比较。通过线性混合效应模型和多元线性回归分析,评价生活方式改变咨询对体重和体成分的影响。结果在为期6个月的试验中,接受生活方式改变咨询的参与者在体重(Δ = - 1.4 kg, p = 0.002)、内脏脂肪(Δ = - 0.53, p = 0.006)、脂肪量(Δ = - 2.16 kg, p <;0.001)和体脂百分比(Δ=−2.02%,p & lt;0.001),与对照组相比。干预组无脂质量(Δ = +0.673 kg, p = 0.068)和骨骼肌百分比(Δ = + 1.27%, p <;0.001),与对照组相比。此外,生活方式改变咨询显著有助于实现至少3%的体重减轻(β = 0.158, p = 0.048)。结论生活方式改变咨询可使体重和身体成分发生有希望和有利的变化。因此,在抗逆转录病毒治疗诊所为超重或肥胖个体提供常规的结构化咨询干预可能有助于减少与肥胖相关的健康风险并改善临床结果(泰国临床试验登记处TCTR20240905007)。
{"title":"Effects of lifestyle modification counselling on weight and body composition among adults with overweight or obesity on antiretroviral therapy: a randomized controlled trial","authors":"Agete Tadewos Hirigo ,&nbsp;Moges Derbe ,&nbsp;Daniel Yilma ,&nbsp;Ayalew Astatkie ,&nbsp;Zelalem Debebe","doi":"10.1016/j.obpill.2025.100184","DOIUrl":"10.1016/j.obpill.2025.100184","url":null,"abstract":"<div><h3>Background</h3><div>we aimed to evaluate the impact of lifestyle modification counselling on weight and body composition among adults with overweight or obesity receiving antiretroviral treatment (ART).</div></div><div><h3>Methods</h3><div>This randomized, open-label, controlled trial enrolled 126 adults aged 18–65 years, living with human immunodeficiency virus (HIV) and classified as overweight or obese. Of these, 116 participants (63 in the control group and 53 in the intervention group) completed the six-month follow-up. Weight and body composition outcomes were analyzed among those who completed the study, with comparisons made between baseline and post-intervention measurements. The effect of lifestyle modification counselling on weight and body composition was evaluated through linear mixed effects model and multiple linear regression analysis.</div></div><div><h3>Results</h3><div>Over the six-month trial, participants who received lifestyle modification counselling showed significantly greater reductions in body weight (Δ = −1.4 kg, p = 0.002), visceral fat (Δ = −0.53, p = 0.006), fat mass (Δ = −2.16 kg, p ​&lt; ​0.001), and body fat percentage (Δ ​= ​−2.02 ​%, p ​&lt; ​0.001) compared to the control group. The intervention group experienced greater increases in fat-free mass (Δ ​= ​+0.673 kg, p ​= ​0.068) and percentage skeletal muscle (Δ ​= ​+1.27 ​%, p ​&lt; ​0.001) compared to the control group. Additionally, lifestyle modification counselling significantly contributed to achieving at least a 3 ​% weight loss from baseline (β ​= ​0.158, p ​= ​0.048).</div></div><div><h3>Conclusion</h3><div>Lifestyle modification counselling resulted in promising and favorable changes in weight and body composition. Therefore, offering routine structured counselling interventions within ART clinics for individuals with overweight or obesity may help reduce obesity-related health risks and improve clinical outcomes (Thai Clinical Trials Registry TCTR20240905007).</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100184"},"PeriodicalIF":0.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144290891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society 支持GLP-1治疗肥胖的营养优先:美国生活方式医学院、美国营养学会、肥胖医学协会和肥胖学会的联合咨询
Pub Date : 2025-06-03 DOI: 10.1016/j.obpill.2025.100181
Dariush Mozaffarian , Monica Agarwal , Monica Aggarwal , Lydia Alexander , Caroline M. Apovian , Shagun Bindlish , Jonathan Bonnet , W. Scott Butsch , Sandra Christensen , Eugenia Gianos , Mahima Gulati , Alka Gupta , Debbie Horn , Ryan M. Kane , Jasdeep Saluja , Deepa Sannidhi , Fatima Cody Stanford , Emily A. Callahan
<div><h3>Background</h3><div>Glucagon-like peptide 1 receptor agonists and combination medications (GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.</div></div><div><h3>Objectives</h3><div>We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician.</div></div><div><h3>Methods</h3><div>An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions.</div></div><div><h3>Results</h3><div>GLP-1s reduce body weight by 5–18 % in trials, with modestly lower effects in real-world analyses, with multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long-term adherence with subsequent weight regain; and high costs with resulting low cost-effectiveness. Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread. Priorities to address this include: (a) patient-centered initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet; and complementary lifestyle interventions. Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s. Emerging areas for more study include dietary modulation of endogenous GLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity.</div></div><div><h3>Conclusions</h3><div>Evidence-based nutritional and lifestyle strategies play a pivotal role to address key challenges around
胰高血糖素样肽1受体激动剂和联合用药(glp -1)正在改变肥胖的治疗前景。然而,现实世界的挑战和有限的临床医生和公众对营养和生活方式干预的认识限制了GLP-1的疗效、公平的结果和成本效益。我们的目的是为临床医生确定与GLP-1治疗肥胖相关的营养和其他生活方式干预的实际优先事项。方法由多个临床和研究学科组成的专家小组,根据专家知识和临床经验,对科学文献进行评估,确定和总结相关主题、重点和新兴方向。结果glp -1在试验中减轻体重5 - 18%,在实际分析中效果较低,具有多种临床益处。挑战包括副作用,尤其是胃肠道;热量减少导致的营养缺乏;肌肉和骨质流失;长期依从性低,随后体重反弹;而高成本带来的低成本效益。许多实践指南建议对成人肥胖患者采用多组分、循证营养和行为疗法,但这种治疗glp -1的方法并不普遍。解决这一问题的优先事项包括:(a)以患者为中心启动glp -1,包括减肥和健康目标;(b)基线筛查,包括通常的饮食习惯、情绪触发因素、饮食失调和相关医疗状况;(c)综合检查,包括肌力、功能和身体成分评估;(d)健康检查的社会决定因素;(e)生活方式评估,包括有氧运动、力量训练、睡眠、精神压力、物质使用和社会关系。在使用GLP-1期间,胃肠道副作用的营养和医疗管理至关重要,正如改变饮食偏好和摄入量,预防营养缺乏,通过阻力训练和适当的饮食来保持肌肉和骨量一样;以及补充性生活方式干预。支持性策略包括团体访问、注册营养师和营养师咨询、远程医疗和数字平台以及食品即医学干预措施。药物获取、食物和营养不安全以及营养和烹饪知识影响glp -1的公平肥胖管理。更多研究的新兴领域包括内源性GLP-1的饮食调节,提高依从性的策略,戒烟后体重维持的营养重点,联合或分阶段强化生活方式管理,以及临床肥胖的诊断标准。结论基于证据的营养和生活方式策略在解决GLP-1治疗肥胖的关键挑战方面发挥着关键作用,使临床医生更有效地促进患者的健康。
{"title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","authors":"Dariush Mozaffarian ,&nbsp;Monica Agarwal ,&nbsp;Monica Aggarwal ,&nbsp;Lydia Alexander ,&nbsp;Caroline M. Apovian ,&nbsp;Shagun Bindlish ,&nbsp;Jonathan Bonnet ,&nbsp;W. Scott Butsch ,&nbsp;Sandra Christensen ,&nbsp;Eugenia Gianos ,&nbsp;Mahima Gulati ,&nbsp;Alka Gupta ,&nbsp;Debbie Horn ,&nbsp;Ryan M. Kane ,&nbsp;Jasdeep Saluja ,&nbsp;Deepa Sannidhi ,&nbsp;Fatima Cody Stanford ,&nbsp;Emily A. Callahan","doi":"10.1016/j.obpill.2025.100181","DOIUrl":"10.1016/j.obpill.2025.100181","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Glucagon-like peptide 1 receptor agonists and combination medications (GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;GLP-1s reduce body weight by 5–18 % in trials, with modestly lower effects in real-world analyses, with multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long-term adherence with subsequent weight regain; and high costs with resulting low cost-effectiveness. Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread. Priorities to address this include: (a) patient-centered initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet; and complementary lifestyle interventions. Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s. Emerging areas for more study include dietary modulation of endogenous GLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Evidence-based nutritional and lifestyle strategies play a pivotal role to address key challenges around ","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100181"},"PeriodicalIF":0.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144471126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term pre-meal whey protein microgel supplementation reduces postprandial glycemia and appetite in adults with overweight: An open-label randomised controlled trial 短期餐前补充乳清蛋白微凝胶可降低超重成人餐后血糖和食欲:一项开放标签随机对照试验
Pub Date : 2025-05-26 DOI: 10.1016/j.obpill.2025.100183
Ian J. Neeland , Kostas Tsintzas , Bo Ahrén , Robert J. Chilton , Ambra Giorgetti , Alric Mondragon , Rachel Ambiaux , Eugenia Migliavacca , David Philippe , Olivier Aprikian , Odd Erik Johansen

Background

Premeal whey protein (WP) consumption may reduce postprandial glucose (PPG) levels and appetite. We assessed the effects of twice daily consumption of a low-dose non-gelling novel WP formulation (WP microgel [WPM]) on PPG, self-reported appetite, and ad-libitum food consumption.

Methods

This was a randomized, prospective, open-label, controlled, single-center crossover study, and adults with BMI 27–35 kg/m2 were randomized to consume either 125 mL of 10 g WPM or control (water) 15 min before breakfast and lunch for four consecutive days. Three days were under free-living conditions, and the 4th day was at the clinic where breakfast (09:00 a.m.) was standardized (323 kcal, 7.0 g proteins), and lunch (12:00 p.m.) ad-libitum (pizza, 228.8 kcal/9.9 g proteins per 100 g). Following a 3-day wash-out, participants were switched to the opposite regimen. The primary confirmatory endpoint was breakfast 2 h-PPG (assessed using CGM) analyzed as iAUC-15-120min using a linear mixed effects model. Appetite was captured by frequent self-reporting (hunger, desire, amount, fullness, satisfaction) using a visual analogue scale (0–100 mm). Ad-libitum food consumption (lunch) was assessed by weighing the amount consumed.

Result

18 individuals (8 females, median age 57 years, BMI 29.8 kg/m2, HbA1c 5.5 %) were randomized and consumed products. The breakfast 2 h-PPG iAUC was 39.3 % lower with WPM compared with control (LSM iAUC Ratio WPM/control (95 % CI): 0.607 [0.4 43, 0.831], p = 0.0047), and during lunch numerically reduced (p = 0.0649). Appetite scores during breakfast and lunch supported a modest suppressing effect of the WPM. Food consumption during the ad-libitum lunch was significantly reduced by 9.4 % (WPM vs Control −66.8 kcal [-133.1, −0.6], p = 0.0482).

Conclusions

A 125 mL pre-meal dose of WPM consumed twice daily before breakfast and lunch for 4 days in adults with obesity significantly reduced breakfast PPG and had a moderate appetite-suppressing effect, which led to a significantly lower energy consumption during ad-libitum lunch (NCT06593769).
餐前乳清蛋白(WP)的摄入可能会降低餐后葡萄糖(PPG)水平和食欲。我们评估了每天两次低剂量非凝胶新型WP制剂(WP微凝胶[WPM])对PPG、自我报告的食欲和随意进食的影响。方法:这是一项随机、前瞻性、开放标签、对照、单中心交叉研究,BMI 27-35 kg/m2的成年人被随机分为两组,分别在早餐和午餐前15分钟饮用125 mL 10 g WPM或对照组(水),连续4天。第三天在自由生活条件下,第四天在诊所,早餐(上午09:00)是标准化的(323千卡,7.0克蛋白质),午餐(中午12:00)是随意的(比萨饼,228.8千卡/9.9克蛋白质/ 100克)。在3天的洗脱期后,参与者被切换到相反的方案。主要验证终点为早餐2 h-PPG(使用CGM评估),使用线性混合效应模型分析为iAUC-15-120min。使用视觉模拟量表(0-100毫米)通过频繁的自我报告(饥饿感、欲望、数量、饱腹感、满意度)来捕获食欲。自由餐(午餐)的消耗量是通过称量消耗量来评估的。结果18例患者(8名女性,中位年龄57岁,BMI 29.8 kg/m2, HbA1c 5.5%)随机入选并食用产品。与对照组相比,WPM在早餐时的2 h-PPG iAUC降低了39.3% (LSM iAUC比WPM/对照(95% CI): 0.607 [0.4 43, 0.831], p = 0.0047),午餐时的iAUC数值降低(p = 0.0649)。早餐和午餐期间的食欲评分支持WPM的适度抑制作用。自由午餐期间的食物消耗显著减少了9.4% (WPM与对照组相比- 66.8 kcal [-133.1, - 0.6], p = 0.0482)。结论肥胖成人每日两次餐前剂量125 mL WPM可显著降低早餐PPG,并有中等食欲抑制作用,可显著降低随意午餐时的能量消耗(NCT06593769)。
{"title":"Short-term pre-meal whey protein microgel supplementation reduces postprandial glycemia and appetite in adults with overweight: An open-label randomised controlled trial","authors":"Ian J. Neeland ,&nbsp;Kostas Tsintzas ,&nbsp;Bo Ahrén ,&nbsp;Robert J. Chilton ,&nbsp;Ambra Giorgetti ,&nbsp;Alric Mondragon ,&nbsp;Rachel Ambiaux ,&nbsp;Eugenia Migliavacca ,&nbsp;David Philippe ,&nbsp;Olivier Aprikian ,&nbsp;Odd Erik Johansen","doi":"10.1016/j.obpill.2025.100183","DOIUrl":"10.1016/j.obpill.2025.100183","url":null,"abstract":"<div><h3>Background</h3><div>Premeal whey protein (WP) consumption may reduce postprandial glucose (PPG) levels and appetite. We assessed the effects of twice daily consumption of a low-dose non-gelling novel WP formulation (WP microgel [WPM]) on PPG, self-reported appetite, and ad-libitum food consumption.</div></div><div><h3>Methods</h3><div>This was a randomized, prospective, open-label, controlled, single-center crossover study, and adults with BMI 27–35 kg/m<sup>2</sup> were randomized to consume either 125 mL of 10 g WPM or control (water) 15 min before breakfast and lunch for four consecutive days. Three days were under free-living conditions, and the 4th day was at the clinic where breakfast (09:00 a.m.) was standardized (323 kcal, 7.0 g proteins), and lunch (12:00 p.m.) ad-libitum (pizza, 228.8 kcal/9.9 g proteins per 100 g). Following a 3-day wash-out, participants were switched to the opposite regimen. The primary confirmatory endpoint was breakfast 2 h-PPG (assessed using CGM) analyzed as iAUC<sub>-15-120min</sub> using a linear mixed effects model. Appetite was captured by frequent self-reporting (hunger, desire, amount, fullness, satisfaction) using a visual analogue scale (0–100 mm). Ad-libitum food consumption (lunch) was assessed by weighing the amount consumed.</div></div><div><h3>Result</h3><div>18 individuals (8 females, median age 57 years, BMI 29.8 kg/m<sup>2</sup>, HbA1c 5.5 %) were randomized and consumed products. The breakfast 2 h-PPG iAUC was 39.3 % lower with WPM compared with control (LSM iAUC Ratio WPM/control (95 % CI): 0.607 [0.4 43, 0.831], p = 0.0047), and during lunch numerically reduced (p = 0.0649). Appetite scores during breakfast and lunch supported a modest suppressing effect of the WPM. Food consumption during the ad-libitum lunch was significantly reduced by 9.4 % (WPM vs Control −66.8 kcal [-133.1, −0.6], p = 0.0482).</div></div><div><h3>Conclusions</h3><div>A 125 mL pre-meal dose of WPM consumed twice daily before breakfast and lunch for 4 days in adults with obesity significantly reduced breakfast PPG and had a moderate appetite-suppressing effect, which led to a significantly lower energy consumption during ad-libitum lunch (NCT06593769).</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100183"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144170096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comorbidities of childhood obesity at a tertiary hospital in Kwazulu-Natal, South Africa 南非夸祖鲁-纳塔尔省一家三级医院儿童肥胖的合并症
Pub Date : 2025-05-24 DOI: 10.1016/j.obpill.2025.100182
Nasheeta Peer , Janice Sewlall , Yusentha Balakrishna , Shafeeka Tayob , Andre-Pascal Kengne , Yasmeen Ganie

Aim

To describe the distribution of childhood obesity and their related comorbidities in <12-year-old children assessed at a South African tertiary hospital from 2012 to 2022.

Methods

In this retrospective electronic chart review, data extracted comprised socio-demographic and lifestyle histories, physical examination and biochemical analyses. World Health Organisation child growth reference defined obesity as z-score ≥2 standard deviations (SD) for 5-19-year-olds, and z-score ≥3 SD for <5-year-olds. Systolic blood pressure and/or diastolic blood pressure ≥95th percentile and 90–94th percentile for age, gender and height, defined hypertension and prehypertension, respectively. Type 2 diabetes and prediabetes diagnoses were based on oral glucose tolerance tests or random blood glucose levels. Dyslipidaemia was deemed present with any abnormality of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides.

Results

Among 430 participants, 52.1 % (n = 224) male, 27.9 % (n = 120) ≤5-years-old and 64.7 % black African, unhealthy lifestyle behaviours were prevalent: 42.3 % spent <30 min/day on physical activity, 43.5 % spent >2 h/day on screen time and 47.9 % consumed soft drinks daily. Family history of obesity (41.9 %), diabetes (40.5 %) and hypertension (40.0 %) was common. Among participants, hypertension (46.1 %) and prehypertension (12.8 %) were high. Type 2 diabetes was low at 1.6 % but prediabetes was 3.3 %. Any dyslipidaemia was prevalent at 30.2 %.

Conclusions

The high burden of cardiometabolic comorbidities in children with obesity warrants concerted interventions at young ages to prevent worsening of comorbidities and the reversal of prehypertension and prediabetes. Unhealthy dietary habits, low activity levels and sedentary behaviours in children need to be urgently targeted to reduce obesity and its comorbidities.
目的描述2012年至2022年在南非某三级医院评估的12岁儿童肥胖及其相关合并症的分布。方法回顾性电子病历回顾,提取的数据包括社会人口统计学和生活方式史、体格检查和生化分析。世界卫生组织儿童生长参考标准将肥胖定义为5-19岁儿童的z-score≥2个标准差(SD), 5岁儿童的z-score≥3个标准差。年龄、性别和身高的收缩压和/或舒张压分别≥95百分位和90 - 94百分位,定义高血压和高血压前期。2型糖尿病和前驱糖尿病的诊断是基于口服葡萄糖耐量试验或随机血糖水平。如果总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇或甘油三酯异常,则认为存在血脂异常。结果在430名参与者中,52.1% (n = 224)的男性、27.9% (n = 120)的≤5岁儿童和64.7%的非洲黑人普遍存在不健康的生活方式行为:42.3%的人每天花30分钟锻炼身体,43.5%的人每天花2小时看屏幕,47.9%的人每天喝软饮料。有肥胖(41.9%)、糖尿病(40.5%)和高血压(40.0%)家族史。在参与者中,高血压(46.1%)和高血压前期(12.8%)较高。2型糖尿病较低,为1.6%,而前驱糖尿病为3.3%。血脂异常发生率为30.2%。结论肥胖儿童心脏代谢合并症的高负担需要在年轻时采取协调一致的干预措施,以防止合并症的恶化和高血压前期和糖尿病前期的逆转。儿童的不健康饮食习惯、低活动水平和久坐行为亟需成为减少肥胖及其合并症的目标。
{"title":"Comorbidities of childhood obesity at a tertiary hospital in Kwazulu-Natal, South Africa","authors":"Nasheeta Peer ,&nbsp;Janice Sewlall ,&nbsp;Yusentha Balakrishna ,&nbsp;Shafeeka Tayob ,&nbsp;Andre-Pascal Kengne ,&nbsp;Yasmeen Ganie","doi":"10.1016/j.obpill.2025.100182","DOIUrl":"10.1016/j.obpill.2025.100182","url":null,"abstract":"<div><h3>Aim</h3><div>To describe the distribution of childhood obesity and their related comorbidities in &lt;12-year-old children assessed at a South African tertiary hospital from 2012 to 2022.</div></div><div><h3>Methods</h3><div>In this retrospective electronic chart review, data extracted comprised socio-demographic and lifestyle histories, physical examination and biochemical analyses. World Health Organisation child growth reference defined obesity as z-score ≥2 standard deviations (SD) for 5-19-year-olds, and z-score ≥3 SD for &lt;5-year-olds. Systolic blood pressure and/or diastolic blood pressure ≥95th percentile and 90–94th percentile for age, gender and height, defined hypertension and prehypertension, respectively. Type 2 diabetes and prediabetes diagnoses were based on oral glucose tolerance tests or random blood glucose levels. Dyslipidaemia was deemed present with any abnormality of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides.</div></div><div><h3>Results</h3><div>Among 430 participants, 52.1 % (n = 224) male, 27.9 % (n = 120) ≤5-years-old and 64.7 % black African, unhealthy lifestyle behaviours were prevalent: 42.3 % spent &lt;30 min/day on physical activity, 43.5 % spent &gt;2 h/day on screen time and 47.9 % consumed soft drinks daily. Family history of obesity (41.9 %), diabetes (40.5 %) and hypertension (40.0 %) was common. Among participants, hypertension (46.1 %) and prehypertension (12.8 %) were high. Type 2 diabetes was low at 1.6 % but prediabetes was 3.3 %. Any dyslipidaemia was prevalent at 30.2 %.</div></div><div><h3>Conclusions</h3><div>The high burden of cardiometabolic comorbidities in children with obesity warrants concerted interventions at young ages to prevent worsening of comorbidities and the reversal of prehypertension and prediabetes. Unhealthy dietary habits, low activity levels and sedentary behaviours in children need to be urgently targeted to reduce obesity and its comorbidities.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100182"},"PeriodicalIF":0.0,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea 指压腕带对GLP-1药物相关恶心的止吐作用
Pub Date : 2025-05-08 DOI: 10.1016/j.obpill.2025.100178
Florencia Ziemke , Soufiane Belarj , Jem Esguerra , Anita Reyes , Nawfal Istfan

Background

Nausea is one of the most reported side effect of GLP-1 receptor agonists (GLP-1a). Current recommendations fall short in taming the symptoms, include antiemetic medication, behavior changes, GLP-1a dose adjustment, and often cause a disruption to treatment. Sea-Band® is a drug-free, class II FDA-cleared medical device for relief of nausea in motion sickness, morning sickness, chemotherapy and anesthesia induced nausea. The device is a set of soft, elastic, reusable acupressure wristbands (ACW) with a skin-facing plastic button worn below the wrist crease applying pressure at acupoint pericardium 6. We hypothesized that ACW was an effective tool for GLP-1a associated nausea.

Methods

This was a one-arm, open-label, non-randomized, prospective interventional study evaluating the antiemetic effect of ACW in non-pregnant adults on GLP-1as with nausea. GLP-1a were semaglutide or tirzepatide. Exclusion criteria were patients on GLP-1a without nausea, recent use of antiemetic medications, other nausea-related conditions, history of gastroparesis, and uncontrolled gastroesophageal reflux disease. Patients were shown how to properly place and use ACW at the onset of nausea and were followed weekly for 4 weeks. Follow-ups assessed frequency of nausea, ACW use frequency and duration, and change in nausea.

Results

359 episodes of nausea were recorded amongst 31 adult participants over 4 weeks. Adults, mean age 55, mean BMI 34, mean HbA1c 5.9 %, reported nausea over 80 % of the time on a weekly basis. ACW were used in all recorded episodes of nausea. Medication doses were kept stable throughout the duration of this study. Nausea relief was achieved within 5 min in one third of episodes, and in over 5 min but under 20 min in the remainder of the episodes. A logistic regression model was used to evaluate the likelihood of nausea relief. A consistent rate of nausea relief over 80 % was observed during the study period, adjusting for the correlation between reduced nausea episodes and reduced episodes.

Conclusion

Although not a controlled trial, this pilot, proof of concept, pragmatic study suggests that ACW may offer a safe, self-administered, reusable, and drug-free option for managing GLP-1a associated nausea.ACW’s nausea reducing effect was seen in over 80 % of episodes, and remained consistent throughout the study period. One third of participants experienced relief within 5 min of wearing ACW in the first three weeks. Given the relatively small sample size of the population, further large-scale investigations are justified. Nausea is common in day-to-day real-world use of GLP-1as, and our results suggest that using ACW may provide a first-line therapeutic intervention used ad libitum to tame a disruptive symptom, improve day-to-day well-being, and positively impact a person’s treatment journey on GLP-1a.
恶心是GLP-1受体激动剂(GLP-1a)报道最多的副作用之一。目前的建议不足以控制症状,包括止吐药物,行为改变,GLP-1a剂量调整,并经常导致治疗中断。Sea-Band®是一种无药物,fda批准的II类医疗器械,用于缓解晕车、孕吐、化疗和麻醉引起的恶心。该设备是一套柔软,弹性,可重复使用的指压腕带(ACW),在手腕折痕下方佩戴一个面向皮肤的塑料按钮,在心包穴位施加压力。我们假设ACW是GLP-1a相关恶心的有效工具。这是一项单臂、开放标签、非随机、前瞻性介入研究,评估ACW对非怀孕成人glp -1伴恶心的止吐效果。GLP-1a为西马鲁肽或替西帕肽。排除标准为服用GLP-1a且无恶心、近期使用止吐药物、其他恶心相关疾病、胃轻瘫史和未控制的胃食管反流疾病的患者。患者被告知如何在恶心开始时正确放置和使用ACW,并每周随访4周。随访评估恶心的频率,ACW的使用频率和持续时间,以及恶心的变化。结果在4周的时间里,31名成人参与者中有359次恶心发作。成年人,平均年龄55岁,平均BMI 34,平均HbA1c 5.9%,每周有超过80%的时间报告恶心。ACW用于所有记录的恶心发作。在整个研究期间,药物剂量保持稳定。三分之一的发作在5分钟内缓解恶心,其余发作在5分钟以上但不到20分钟。采用logistic回归模型评估恶心缓解的可能性。在研究期间,观察到恶心缓解率超过80%,调整了恶心发作减少和发作减少之间的相关性。结论:虽然不是对照试验,但这项试点、概念验证和实用研究表明,ACW可能为治疗GLP-1a相关的恶心提供了一种安全、自我给药、可重复使用和无药物的选择。ACW减轻恶心的效果在80%以上的发作中可见,并在整个研究期间保持一致。三分之一的参与者在头三周佩戴ACW后5分钟内感到缓解。考虑到人口的样本量相对较小,进一步的大规模调查是合理的。恶心在日常使用GLP-1a中很常见,我们的研究结果表明,使用ACW可能提供一线治疗干预,可以随意使用,以抑制破坏性症状,改善日常幸福感,并对患者的GLP-1a治疗过程产生积极影响。
{"title":"Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea","authors":"Florencia Ziemke ,&nbsp;Soufiane Belarj ,&nbsp;Jem Esguerra ,&nbsp;Anita Reyes ,&nbsp;Nawfal Istfan","doi":"10.1016/j.obpill.2025.100178","DOIUrl":"10.1016/j.obpill.2025.100178","url":null,"abstract":"<div><h3>Background</h3><div>Nausea is one of the most reported side effect of GLP-1 receptor agonists (GLP-1a). Current recommendations fall short in taming the symptoms, include antiemetic medication, behavior changes, GLP-1a dose adjustment, and often cause a disruption to treatment. Sea-Band® is a drug-free, class II FDA-cleared medical device for relief of nausea in motion sickness, morning sickness, chemotherapy and anesthesia induced nausea. The device is a set of soft, elastic, reusable acupressure wristbands (ACW) with a skin-facing plastic button worn below the wrist crease applying pressure at acupoint pericardium 6. We hypothesized that ACW was an effective tool for GLP-1a associated nausea.</div></div><div><h3>Methods</h3><div>This was a one-arm, open-label, non-randomized, prospective interventional study evaluating the antiemetic effect of ACW in non-pregnant adults on GLP-1as with nausea. GLP-1a were semaglutide or tirzepatide. Exclusion criteria were patients on GLP-1a without nausea, recent use of antiemetic medications, other nausea-related conditions, history of gastroparesis, and uncontrolled gastroesophageal reflux disease. Patients were shown how to properly place and use ACW at the onset of nausea and were followed weekly for 4 weeks. Follow-ups assessed frequency of nausea, ACW use frequency and duration, and change in nausea.</div></div><div><h3>Results</h3><div>359 episodes of nausea were recorded amongst 31 adult participants over 4 weeks. Adults, mean age 55, mean BMI 34, mean HbA1c 5.9 %, reported nausea over 80 % of the time on a weekly basis. ACW were used in all recorded episodes of nausea. Medication doses were kept stable throughout the duration of this study. Nausea relief was achieved within 5 min in one third of episodes, and in over 5 min but under 20 min in the remainder of the episodes. A logistic regression model was used to evaluate the likelihood of nausea relief. A consistent rate of nausea relief over 80 % was observed during the study period, adjusting for the correlation between reduced nausea episodes and reduced episodes.</div></div><div><h3>Conclusion</h3><div>Although not a controlled trial, this pilot, proof of concept, pragmatic study suggests that ACW may offer a safe, self-administered, reusable, and drug-free option for managing GLP-1a associated nausea.ACW’s nausea reducing effect was seen in over 80 % of episodes, and remained consistent throughout the study period. One third of participants experienced relief within 5 min of wearing ACW in the first three weeks. Given the relatively small sample size of the population, further large-scale investigations are justified. Nausea is common in day-to-day real-world use of GLP-1as, and our results suggest that using ACW may provide a first-line therapeutic intervention used ad libitum to tame a disruptive symptom, improve day-to-day well-being, and positively impact a person’s treatment journey on GLP-1a.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100178"},"PeriodicalIF":0.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining effects of sleeve gastrectomy in an urban youth population 探讨袖式胃切除术在城市青年人群中的效果
Pub Date : 2025-05-08 DOI: 10.1016/j.obpill.2025.100179
L.B. Ditchek , J. Zitsman , J. Woo Baidal , S.E. Oberfield , I. Fennoy

Background

Extensive evidence demonstrates the positive health effects of metabolic and bariatric surgery (MBS) in adolescents, including a reduction in body mass index (BMI) and improvements in cardiometabolic health. However, studies often lack generalizability due to their inclusion of predominately non-Hispanic White and privately insured patients.

Methods

This retrospective study aims to provide insight into MBS outcomes for an urban youth population.

Results

All groups showed a statistically significant improvement in BMI, HgbA1c, HDL, and triglyceride levels, postoperatively. Postoperative BMI did not differ between Non-Hispanic and Hispanic participants (P = 0.45) or between publicly and privately insured patients (P = 0.52). There was a statistically significantly lower postoperative HgbA1c in non-Hispanic participants compared to Hispanic participants (P = 0.01) and a statistically significantly lower postoperative Systolic blood pressure (SBP) in privately insured patients compared to publicly insured patient (P = 0.02). No other significant differences were detected between privately/publicly insured and Hispanic/non-Hispanic outcomes at 12 months postoperatively.

Conclusion

In our urban youth patient population, MBS resulted in significant improvement in BMI across all groups. Notably, there were no statistically significant differences in preoperative characteristics (BMI, HgbA1, LDL, HDL, triglycerides, total cholesterol, SBP or DBP). However, postoperative differences in HgbA1c and SBP were detected between groups. The reasons behind these differences remain unclear, emphasizing the need for further research with greater population variability. This study underscores the importance of increasing generalizability in studies of MBS to fully understand outcomes in underrepresented groups.
背景大量证据表明,代谢和减肥手术(MBS)对青少年的健康有积极影响,包括身体质量指数(BMI)的降低和心脏代谢健康的改善。然而,研究往往缺乏普遍性,因为他们主要包括非西班牙裔白人和私人保险患者。方法本回顾性研究旨在深入了解MBS对城市青年人口的影响。结果两组患者术后BMI、hba1c、HDL、甘油三酯水平均有显著改善。术后BMI在非西班牙裔和西班牙裔参与者之间没有差异(P = 0.45),在公共和私人保险患者之间也没有差异(P = 0.52)。与西班牙裔患者相比,非西班牙裔患者术后hba1c显著降低(P = 0.01),私人参保患者术后收缩压显著低于公共参保患者(P = 0.02)。术后12个月,私人/公共保险和西班牙裔/非西班牙裔结果之间没有发现其他显著差异。结论:在我们的城市青年患者人群中,MBS导致所有组的BMI显著改善。值得注意的是,两组术前特征(BMI、HgbA1、LDL、HDL、甘油三酯、总胆固醇、收缩压、舒张压)差异无统计学意义。但术后各组间hba1c和收缩压存在差异。这些差异背后的原因尚不清楚,强调需要进一步研究更大的人口变异性。这项研究强调了在MBS研究中增加普遍性的重要性,以充分了解代表性不足群体的结果。
{"title":"Examining effects of sleeve gastrectomy in an urban youth population","authors":"L.B. Ditchek ,&nbsp;J. Zitsman ,&nbsp;J. Woo Baidal ,&nbsp;S.E. Oberfield ,&nbsp;I. Fennoy","doi":"10.1016/j.obpill.2025.100179","DOIUrl":"10.1016/j.obpill.2025.100179","url":null,"abstract":"<div><h3>Background</h3><div>Extensive evidence demonstrates the positive health effects of metabolic and bariatric surgery (MBS) in adolescents, including a reduction in body mass index (BMI) and improvements in cardiometabolic health. However, studies often lack generalizability due to their inclusion of predominately non-Hispanic White and privately insured patients.</div></div><div><h3>Methods</h3><div>This retrospective study aims to provide insight into MBS outcomes for an urban youth population.</div></div><div><h3>Results</h3><div>All groups showed a statistically significant improvement in BMI, HgbA1c, HDL, and triglyceride levels, postoperatively. Postoperative BMI did not differ between Non-Hispanic and Hispanic participants (P = 0.45) or between publicly and privately insured patients (P = 0.52). There was a statistically significantly lower postoperative HgbA1c in non-Hispanic participants compared to Hispanic participants (P = 0.01) and a statistically significantly lower postoperative Systolic blood pressure (SBP) in privately insured patients compared to publicly insured patient (P = 0.02). No other significant differences were detected between privately/publicly insured and Hispanic/non-Hispanic outcomes at 12 months postoperatively.</div></div><div><h3>Conclusion</h3><div>In our urban youth patient population, MBS resulted in significant improvement in BMI across all groups. Notably, there were no statistically significant differences in preoperative characteristics (BMI, HgbA1, LDL, HDL, triglycerides, total cholesterol, SBP or DBP). However, postoperative differences in HgbA1c and SBP were detected between groups. The reasons behind these differences remain unclear, emphasizing the need for further research with greater population variability. This study underscores the importance of increasing generalizability in studies of MBS to fully understand outcomes in underrepresented groups.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100179"},"PeriodicalIF":0.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The introduction of a new mobile lifestyle tool in the battle against hypothalamic obesity; the “HAPPYthalamus” application 在与下丘脑肥胖的斗争中引入新的移动生活方式工具;“HAPPYthalamus”应用
Pub Date : 2025-05-02 DOI: 10.1016/j.obpill.2025.100177
I.M.A.A. van Roessel , M.J. de Koning , M.V. Birk , J. Blom , J. Dekker , E.J.M. Feskens , J.P. de Graaf , Y. Lu , D.A. Lucassen , E. Pondaag , W.J.E. Tissing , H.M. van Santen

Background

Children with hypothalamic dysfunction may experience hypothalamic weight gain, marked by severe hyperphagia, low energy expenditure, and reduced initiative. We developed the mobile app “HAPPYthalamus” to support these children by promoting exercise, providing distraction from hyperphagia, and rewarding healthy behavior. This study evaluated the app's usability and patient satisfaction.

Methods

This was a non-randomized, explorative intervention study. Children (8–18 years) with hypothalamic dysfunction and a suprasellar brain tumor were included. Patients were instructed to use the mobile application (app) for six months. We applied a mixed-methods design evaluating app use and satisfaction through questionnaires and semi-structured interviews.

Results

Of 22 patients, 15 scored positive on learning to use the app. Positive effects on eating distraction were reported by 9 patients. The app was not well adapted to different age groups; some found the challenges motivating while others were indifferent to winning challenges and forgot the app due to limited variety. Overall, 64% of the children indicated the app should be part of the standard of care.

Conclusions

A mobile app as a lifestyle buddy for children with hypothalamic dysfunction is useable but needs improvements. Adapting to age groups and incorporating behavioral change theories, gamification, and reward systems could enhance engagement and support a healthier lifestyle.
背景:患有下丘脑功能障碍的儿童可能会经历下丘脑体重增加,表现为严重的贪食、低能量消耗和主动性降低。我们开发了移动应用“HAPPYthalamus”来支持这些孩子,通过促进运动,分散他们对贪食的注意力,并奖励健康的行为。这项研究评估了应用程序的可用性和患者满意度。方法非随机、探索性干预研究。伴有下丘脑功能障碍和鞍上脑肿瘤的儿童(8-18岁)被纳入研究对象。患者被指示使用移动应用程序(app) 6个月。我们采用混合方法设计,通过问卷调查和半结构化访谈来评估应用程序的使用和满意度。结果在22名患者中,15名患者在学习使用该应用程序方面得分为阳性。9名患者报告了对进食分心的积极影响。这款应用并没有很好地适应不同的年龄组;有些人觉得挑战很有动力,而另一些人则对赢得挑战漠不关心,因为种类有限而忘记了这款应用。总体而言,64%的孩子表示该应用程序应该成为标准护理的一部分。结论手机app作为下丘脑功能障碍儿童的生活伙伴是可行的,但仍需改进。适应不同的年龄组,结合行为改变理论、游戏化和奖励制度,可以提高参与度,支持更健康的生活方式。
{"title":"The introduction of a new mobile lifestyle tool in the battle against hypothalamic obesity; the “HAPPYthalamus” application","authors":"I.M.A.A. van Roessel ,&nbsp;M.J. de Koning ,&nbsp;M.V. Birk ,&nbsp;J. Blom ,&nbsp;J. Dekker ,&nbsp;E.J.M. Feskens ,&nbsp;J.P. de Graaf ,&nbsp;Y. Lu ,&nbsp;D.A. Lucassen ,&nbsp;E. Pondaag ,&nbsp;W.J.E. Tissing ,&nbsp;H.M. van Santen","doi":"10.1016/j.obpill.2025.100177","DOIUrl":"10.1016/j.obpill.2025.100177","url":null,"abstract":"<div><h3>Background</h3><div>Children with hypothalamic dysfunction may experience hypothalamic weight gain, marked by severe hyperphagia, low energy expenditure, and reduced initiative. We developed the mobile app “HAPPYthalamus” to support these children by promoting exercise, providing distraction from hyperphagia, and rewarding healthy behavior. This study evaluated the app's usability and patient satisfaction.</div></div><div><h3>Methods</h3><div>This was a non-randomized, explorative intervention study. Children (8–18 years) with hypothalamic dysfunction and a suprasellar brain tumor were included. Patients were instructed to use the mobile application (app) for six months. We applied a mixed-methods design evaluating app use and satisfaction through questionnaires and semi-structured interviews.</div></div><div><h3>Results</h3><div>Of 22 patients, 15 scored positive on learning to use the app. Positive effects on eating distraction were reported by 9 patients. The app was not well adapted to different age groups; some found the challenges motivating while others were indifferent to winning challenges and forgot the app due to limited variety. Overall, 64% of the children indicated the app should be part of the standard of care.</div></div><div><h3>Conclusions</h3><div>A mobile app as a lifestyle buddy for children with hypothalamic dysfunction is useable but needs improvements. Adapting to age groups and incorporating behavioral change theories, gamification, and reward systems could enhance engagement and support a healthier lifestyle.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"15 ","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating remote high-intensity interval training into multi-component obesity treatment for adolescents: Impacts on body composition, fitness, and lifestyle 将远程高强度间歇训练纳入青少年多成分肥胖治疗:对身体成分、健康和生活方式的影响
Pub Date : 2025-04-26 DOI: 10.1016/j.obpill.2025.100176
Fábio de Freitas , Mariana R. Zago , Maria Ângela Antônio , Maria Ângela Bellomo Brandão , António Videira-Silva

Background

This study aimed to analyze the effects of a three-month remote High-Intensity Interval Training (HIIT) program as an adjunct to a multi-component clinical obesity treatment on body composition, physical fitness, movement behaviors, and nutritional habits in adolescents with obesity.

Methods

This study was designed as a non-randomized controlled trial involving a total of 100 adolescents with obesity (BMI z-score ≥2), aged 12–17, divided into a control group (CG, receiving only standard care, i.e., medical and nutritional guidance, n = 50), and an experimental group (EG, exposed to a remote HIIT program four times/week (∼20 min/session) for 3 months, additionally to standard care, n = 50). Intervention effect was analyzed based on adherence (presence in ≥80 % of sessions). Anthropometrics, body composition, and physical fitness data were assessed at baseline and at the end of the intervention. Changes in body composition and physical fitness were the primary outcomes, while movement behaviors and nutritional habits were considered secondary outcomes.

Results

Six participants were excluded from the analysis due to missing post-intervention assessments. Among the 44 (88 %) adolescents who completed the 3-month assessments, 28 were included in the adherents’ group (AG) and 16 in non-adherents (non-AG). BMI z-score significantly decreased over time (β = −0.08, p = 0.001), with the AG showing a more significant reduction than non-AG (β = −0.3, p < 0.001) and CG (β = −0.29, p < 0.001). Flexibility (β = 3.5, p < 0.001) and Core strength improved (β = 2.9, p = 0.002), with no differences between the AG and non-AG. Water consumption also increased (β = 0.2, p = 0.022), but only in the AG.

Conclusion

The remote HIIT program was effective in improving body composition and physical fitness in adolescents with obesity. These findings highlight the potential of remote exercise interventions as a feasible and beneficial strategy within multi-component obesity treatments.
本研究旨在分析为期三个月的远程高强度间歇训练(HIIT)计划作为多成分临床肥胖治疗的辅助手段,对肥胖青少年的身体成分、体能、运动行为和营养习惯的影响。方法本研究设计为一项非随机对照试验,共涉及100名12-17岁的肥胖青少年(BMI z-score≥2),分为对照组(CG,仅接受标准治疗,即医疗和营养指导,n = 50)和实验组(EG,每周接受4次远程HIIT计划(~ 20分钟/次),持续3个月,另外接受标准治疗,n = 50)。根据依从性(≥80%的疗程)分析干预效果。在基线和干预结束时评估人体测量学、身体成分和身体健康数据。身体组成和身体健康的变化是主要结果,而运动行为和营养习惯被认为是次要结果。结果6名受试者因缺少干预后评估而被排除在分析之外。在完成3个月评估的44名(88%)青少年中,28名被纳入依从组(AG), 16名被纳入非依从组(non-AG)。BMI z-score随时间显著下降(β = - 0.08, p = 0.001), AG组比非AG组下降更显著(β = - 0.3, p <;0.001)和CG (β = - 0.29, p <;0.001)。灵活性(β = 3.5, p <;0.001)和核心强度提高(β = 2.9, p = 0.002), AG和非AG之间无差异。水分消耗也增加(β = 0.2, p = 0.022),但仅在AG中增加。结论远程HIIT训练能有效改善青少年肥胖患者的身体组成和体质。这些发现强调了远程运动干预在多组分肥胖治疗中作为一种可行且有益的策略的潜力。
{"title":"Integrating remote high-intensity interval training into multi-component obesity treatment for adolescents: Impacts on body composition, fitness, and lifestyle","authors":"Fábio de Freitas ,&nbsp;Mariana R. Zago ,&nbsp;Maria Ângela Antônio ,&nbsp;Maria Ângela Bellomo Brandão ,&nbsp;António Videira-Silva","doi":"10.1016/j.obpill.2025.100176","DOIUrl":"10.1016/j.obpill.2025.100176","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to analyze the effects of a three-month remote High-Intensity Interval Training (HIIT) program as an adjunct to a multi-component clinical obesity treatment on body composition, physical fitness, movement behaviors, and nutritional habits in adolescents with obesity.</div></div><div><h3>Methods</h3><div>This study was designed as a non-randomized controlled trial involving a total of 100 adolescents with obesity (BMI z-score ≥2), aged 12–17, divided into a control group (CG, receiving only standard care, i.e., medical and nutritional guidance, n = 50), and an experimental group (EG, exposed to a remote HIIT program four times/week (∼20 min/session) for 3 months, additionally to standard care, n = 50). Intervention effect was analyzed based on adherence (presence in ≥80 % of sessions). Anthropometrics, body composition, and physical fitness data were assessed at baseline and at the end of the intervention. Changes in body composition and physical fitness were the primary outcomes, while movement behaviors and nutritional habits were considered secondary outcomes.</div></div><div><h3>Results</h3><div>Six participants were excluded from the analysis due to missing post-intervention assessments. Among the 44 (88 %) adolescents who completed the 3-month assessments, 28 were included in the adherents’ group (AG) and 16 in non-adherents (non-AG). BMI z-score significantly decreased over time (β = −0.08, p = 0.001), with the AG showing a more significant reduction than non-AG (β = −0.3, p &lt; 0.001) and CG (β = −0.29, p &lt; 0.001). Flexibility (β = 3.5, p &lt; 0.001) and Core strength improved (β = 2.9, p = 0.002), with no differences between the AG and non-AG. Water consumption also increased (β = 0.2, p = 0.022), but only in the AG.</div></div><div><h3>Conclusion</h3><div>The remote HIIT program was effective in improving body composition and physical fitness in adolescents with obesity. These findings highlight the potential of remote exercise interventions as a feasible and beneficial strategy within multi-component obesity treatments.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"14 ","pages":"Article 100176"},"PeriodicalIF":0.0,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143895660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Obesity Pillars
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1